Cui Na, Feng Xiaoye, Zhao Zhiming, Zhang Jie, Xu Yueming, Wang Luning, Hao Guimin
Department of Reproduction, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Department of Reproduction, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Clin Ther. 2017 Apr;39(4):751-758. doi: 10.1016/j.clinthera.2017.02.007. Epub 2017 Mar 11.
Polycystic ovary syndrome (PCOS) is a metabolic and endocrinal disorder affecting a number of women of reproductive age. We aimed to reveal the correlation between the endocannabinoid system and PCOS, which may provide a new therapeutic target for PCOS treatment.
Serum levels of anandamide and 2-arachidonoylglycerol andexpression of cannabinoid receptors and fatty acid amide hydrolase (FAAH) in the endometrium were compared between women with PCOS and infertile women without PCOS, as well as women with PCOS before and after treatment with Diane-35 and metformin. Cannabinoid receptors and FAAH in the endometrium were stained using the immunohistochemical method. Results were analyzed by calculating integrated optical density.
Plasma anandamide was increased significantly in women with PCOS compared with infertile women without PCOS. Treatment with Diane-35 and metformin reversed this increase in women with PCOS. No significant difference in 2-arachidonoylglycerol was observed between the infertile women with or without PCOS. The women with PCOS had lower endometrial expression of FAAH compared with infertile women without PCOS, whereas no significant difference in endometrial expression of cannabinoid receptors was observed between the women with PCOS and infertile women without PCOS. We found that after treatment with Diane-35 and metformin, FAAH expression tended toward a significant increase compared with women before the treatment.
Endocannabinoid system may be involved in the progression of PCOS, and serum anandamide could serve as a potential biomarker of clinical diagnosis of PCOS.
多囊卵巢综合征（PCOS）是一种影响许多育龄女性的代谢和内分泌紊乱疾病。我们旨在揭示内源性大麻素系统与PCOS之间的相关性，这可能为PCOS治疗提供新的治疗靶点。
比较PCOS女性与无PCOS的不孕女性之间，以及PCOS女性在使用达英-35和二甲双胍治疗前后，血清中花生四烯乙醇胺和2-花生四烯酸甘油酯的水平，以及子宫内膜中大麻素受体和脂肪酸酰胺水解酶（FAAH）的表达。采用免疫组织化学方法对子宫内膜中的大麻素受体和FAAH进行染色。通过计算积分光密度分析结果。
与无PCOS的不孕女性相比，PCOS女性血浆中花生四烯乙醇胺显著升高。达英-35和二甲双胍治疗可逆转PCOS女性的这种升高。有无PCOS的不孕女性之间未观察到2-花生四烯酸甘油酯有显著差异。与无PCOS的不孕女性相比，PCOS女性子宫内膜中FAAH的表达较低，而PCOS女性与无PCOS的不孕女性之间子宫内膜中大麻素受体的表达未观察到显著差异。我们发现，与治疗前的女性相比，达英-35和二甲双胍治疗后，FAAH表达有显著增加的趋势。
内源性大麻素系统可能参与PCOS的进展，血清花生四烯乙醇胺可作为PCOS临床诊断的潜在生物标志物。
